Novo Nordisk Foundation Launches 3 European Obesity-Drug Incubators
Updated
Updated · Bloomberg · Jun 19
Novo Nordisk Foundation Launches 3 European Obesity-Drug Incubators
1 articles · Updated · Bloomberg · Jun 19
Summary
London will host the first CardioMetabolic Bridge incubator this month, the first site in a new Novo Nordisk Foundation network aimed at obesity and diabetes research.
The program is designed to turn academic discoveries into commercial ventures, with the foundation seeking breakthrough cardiometabolic treatments through earlier-stage company building.
Italy and Germany will get additional sites later in 2026, expanding the incubator network across Europe.
The launch extends the reach of the foundation that controls Novo Nordisk, the Danish drugmaker behind Ozempic, into startup creation around high-demand metabolic medicines.
Europe's biotech sector lags behind the US. Can the Ozempic foundation's new program finally close the 'commercialisation gap'?
The owner of Ozempic is funding future obesity treatments. What could this mean for the price of next-generation drugs?
Will these new incubators prioritize blockbuster drugs over more accessible, preventative health solutions for the public?
Novo Nordisk Foundation’s €347 Million CardioMetabolic Bridge: Transforming European Health Innovation and Access
Overview
On June 19, 2026, the first CardioMetabolic Bridge incubator officially launched in London, marking the start of a new network of specialized hubs across Europe. Spearheaded by the owner of Novo Nordisk, this initiative aims to accelerate the development of breakthrough treatments for cardiometabolic diseases by bridging the gap between academic research and commercial ventures. With additional incubators planned in Italy and Germany, the program forms a comprehensive European strategy to tackle major health challenges. By addressing funding barriers, the CardioMetabolic Bridge seeks to ensure that life-saving innovations reach the patients who need them most.